NEW YORK (GenomeWeb) – The GenomeWeb Index fell nearly 1 percent in April, as disappointing preliminary earnings from Illumina and some concerns about whether Abbott would complete its acquisition of Alere dragged down the stocks of those firms.

The Dow Jones Industrial Average, which gained less than 1 percent during the month, and the Nasdaq Biotechnology Index, which gained 3 percent, outperformed the GenomeWeb Index. However, the Index outperformed the Nasdaq, which finished the month nearly 2 percent lower.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.